English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213818
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Extended treatment of cancer-associated thrombosis

AuthorsMarín-Romero, Samira; Jara Palomares, Luis
Venous thromboembolism
Extended treatment
Issue DateSep-2019
CitationThrombosis Research 181: 1-9 (2019)
AbstractVenous thromboembolism (VTE) is a growing concern in patients with cancer. Current guidelines recommend that cancer patients with VTE should receive anticoagulation for at least 3–6 months. However, the question as to whether anticoagulants should be continued after 3 to 6 months of treatment remains open. In presence of an active malignancy, physicians should weigh the benefits and burdens of ongoing anticoagulation taking into account the clinical status, patient expectations, and the risk of bleeding. As the length of time from the index event increases, the available evidence is not conclusive. The most critical unresolved issues include the decision to continue or discontinue anticoagulation and the selection of the most appropriate anticoagulant agent. On this background, our article provides an overview of the available studies focusing on extended (i.e., >6 months) anticoagulation treatment in cancer-associated thrombosis, with the ultimate goal of refining real-world clinical decision-making in this patient population.
Publisher version (URL)http://dx.doi.org/10.1016/j.thromres.2019.07.003
Identifiersdoi: 10.1016/j.thromres.2019.07.003
issn: 0049-3848
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.